GEN Exclusives

More »

GEN News Highlights

More »
May 18, 2011

Goodwin Biotechnology and Rafagen Ink Deal for Biomanufacturing and Cell-Line Development

  • Goodwin Biotechnology (GBI), a contract biomanufacturing company, and Rafagen, a provider of engineered cell lines for protein and mAb production,are joining forces. Their collaborative agreement covers cell line engineering and biological contract manufacturing.

    "By collaborating with Rafagen for cell-line engineering, we at GBI can expand our capabilities as a biological contract manufacturing organization and offer one-stop shopping," comments SooYoung Lee, Ph.D., svp at GBI.

    "This enables our clients to overcome challenging projects by working from their cDNA to develop more robust and high-productivity cell lines that will not only scale up with greater efficiency, but by identifying cell lines with the highest level of efficacy, the end product will hopefully optimize patient outcomes," Dr. Lee says.

    Rafagen develops and commercializes gene-expression systems. The company uses FACS-aided and nonantibody-based technology for the selection of highly expressing cell lines. “The highest producing cell lines will be established at a fraction of the time currently required," states Sung Ho Hahm, Ph.D., co-founder and president / CEO of Ragagen.

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Easing Restrictions for Terminal Patients

Should the Federal Government Pass a “Right to Try” Bill Allowing Terminally Ill Patients Access to Experimental Medicines?

More »